MAP2K7 and cancer: In addition to the previously published gene expression signature scores representing MEK-inhibitor sensitivity and MEK-inhibitor adaptive resistance [83,84], SFAB could serve as a predictive biomarker for successful cancer therapy by MEK inhibition.